#obesity-treatment

#obesity-treatment

Pharmacies advocate for stricter oversight of online weight-loss jab sales to ensure patient safety through proper consultations.

Medicare may cover anti-obesity drug Wegovy for cardiovascular risks

Drug companies seek FDA approval for weight-loss drugs for various other conditions

The high cost of weight-loss drugs severely limits patient access, pushing many toward unsafe alternatives.

Ozempic impacts metabolism as well as appetite, indicating obesity treatment is complex and more than just diet and exercise.

Novo Nordisk's Amycretin shows promise for rapid weight loss, potentially surpassing current leading drugs like Wegovy and Ozempic.

GLP-1 receptor agonists not only aid in weight loss but also influence various health conditions positively and negatively.

Eli Lilly aims to develop a once-per-year weight-loss shot for easier obesity management.

Innovative Endoscopic Sleeve Gastroplasty procedure positively impacts obesity treatment and patient well-being.

Novo Nordisk's Wegovy reduces COVID-19 mortality risk by one-third in obese patients, indicating potential health benefits beyond obesity treatment.

Novo Nordisk faces challenges in sustaining growth with competition in obesity treatments, particularly after CagriSema's trial results.

The FDA is considering removing Wegovy from its shortage list, which impacts compounded versions being provided to patients.

Compounded drugs are filling the gap for many patients who can't afford or find Wegovy, highlighting their role in treatment options.

Novo Nordisk's Amycretin shows greater weight loss potential than Wegovy in early trials, marking a significant development in obesity treatment.

Novo Nordisk's weight loss drugs are effective but criticized for their high costs and accessibility issues in the U.S.

GLP-1 drugs may reduce cravings for alcohol and other addictions while also addressing obesity and other health conditions.

Lasker Awards highlight significant contributions to medical research, recognizing advances in obesity treatment through GLP-1-based drugs.

GLP-1 drugs have the potential to significantly impact obesity and multiple chronic diseases, shaping healthcare for years to come.

The FDA's decision will phase out off-brand copies of obesity and diabetes drugs, affecting access and pricing for consumers.

Zepbound leads to more weight loss than Wegovy in clinical trials.

Eli Lilly's Zepbound pricing strategy has both improved access with lower starter dosages while raising concerns over transparency with existing drug prices.

GLP-1 drugs have significant roles beyond diabetes and obesity treatment, engaging multiple body systems and presenting new avenues for chronic condition research.

Mounjaro is an effective treatment option for obesity and type 2 diabetes, approved for use with diet and physical activity.

GLP-1 receptor agonists offer effective treatment for obesity and T2D, but their impact is reduced in individuals with both conditions.

Employers are increasingly offering health benefits for weight loss drugs, impacting healthcare costs amidst high demand and rising obesity rates.

NHS warns against the inappropriate use of weight-loss drugs without medical supervision.

People with obesity now have a choice between semaglutide and tirzepatide for weight loss, but deciding which to take is complex.

Medicaid plans not required to cover Wegovy for weight loss/obesity, despite effectiveness, due to old law.

Genetic test MyPhenome can predict response to weight-loss drug semaglutide with 75% accuracy, categorizing people into four types of weight gain.

Weight loss drugs shift stigma around obesity and shame associated with dieting.

Patients feel shamed for using weight loss drugs, highlighting internal and external biases.

High prices for diabetes and obesity drugs like Ozempic are jeopardizing patient access, especially among low-income and minority groups.

Wegovy launches in China at lower prices than the US, but patients must bear costs individually.

Wegovy now approved for reducing cardiovascular risks in adults with heart disease and obesity

F.D.A. approval based on study showing Wegovy reduced heart attacks and strokes

The UK is exploring pilot schemes to improve obesity care with pharmaceutical companies, focusing on economic outcomes rather than individual health benefits.

Viking Therapeutics' VK2735 obesity treatment stock presents a promising investment opportunity ahead of its Phase 3 trials due to recent positive data.

GLP-1 receptor agonists may help treat addiction-related issues such as obesity and substance use disorders, demonstrating positive effects on cravings and overdose risks.

GLP-1 receptor agonists have potential benefits beyond just treating diabetes and obesity, potentially impacting diseases like Alzheimer's and Parkinson's positively.

The Lasker Awards honor scientists for transformative contributions to medicine, particularly in obesity treatment through GLP-1 hormone research.

Understanding the differences between obesity drugs can lead to personalized treatment strategies.

New research shows varying effectiveness among drugs like semaglutide and tirzepatide in metabolic improvements.

GLP-1 medications significantly boost metabolic activity and contribute to weight loss, contradicting the belief that they merely suppress appetite.